利伐沙班的作用及功效

Rivaroxaban exerts its anticoagulant effect mainly by inhibiting the activity of coagulation factor Xa, thereby reducing the generation of thrombin (coagulation factor IIa). It does not affect the activity of generated thrombin, so it has little impact on physiological hemostasis. As a new oral anticoagulant, rivaroxaban has been widely used for the prevention and treatment of venous thromboembolic diseases and the prevention of stroke in non-valvular atrial fibrillation. Today we will learn about the functions and efficacy of rivaroxaban.

Rivaroxaban, has been approved for the prevention of venous thrombosis (VTE) in adult patients undergoing hip or knee replacement surgery; and for the treatment of deep vein thrombosis (DVT) in adults to reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT.

In terms of administration: 1. After carefully evaluating the benefits of treatment and the risk of bleeding, the duration of treatment should be determined based on individual circumstances. Short-term treatment (3 months) should be based on transient risk factors (eg, recent surgery, trauma, immobilization), and long-term treatment should be based on permanent risk factors or idiopathic DVT. There is insufficient experience with the use of rivaroxaban for more than 12 months for this indication.

2. If a missed dose occurs during 15 mg twice daily treatment (days 1-21), the patient should take rivaroxaban immediately to ensure that 30 mg of rivaroxaban is taken daily. In this case, it may be necessary to take two 15 mg tablets at once. Thereafter, regular 15 mg twice daily dosing should be continued as recommended. If a missed dose occurs during 20 mg once-daily treatment (day 22 and beyond), the patient should begin rivaroxaban immediately and continue to receive once-daily dosing at the recommended dose thereafter. The dose should not be doubled in one day to make up for a missed dose.

3. For adult patients with non-valvular atrial fibrillation to reduce the risk of stroke and systemic embolism, the recommended dose is 20 mg once a day, which is also the maximum recommended dose. For patients with low body weight and advanced age (>75 years old), doctors can use 15 mg once a day as appropriate based on the patient's condition.

If anticoagulant therapy must be discontinued to reduce the risk of bleeding during surgery or other intervention, rivaroxaban must be discontinued at least 242 hours before the intervention to reduce the risk of bleeding. Given the rapid onset of action of rivaroxaban, rivaroxaban should be reintroduced as soon as adequate hemostasis is determined after surgery or other interventional procedures. If oral medications cannot be taken during or after surgical intervention, consider administering a non-oral anticoagulant.

The above is the function and efficacy of rivaroxaban. I hope it can help you!